Notice of Single-Award Deviation From Competition Requirements for the Severe Combined Immunodeficiency (SCID) Newborn Screening Program at the Jeffrey Modell Foundation, 44191 [2017-20116]

Download as PDF Federal Register / Vol. 82, No. 182 / Thursday, September 21, 2017 / Notices Staff (see ADDRESSES). A link to the transcript will also be available on the internet at https://www.fda.gov/ AnimalVeterinary/SafetyHealth/ AntimicrobialResistance/ NationalAntimicrobial ResistanceMonitoringSystem/ ucm059172.htm. Dated: September 15, 2017. Anna K. Abram, Deputy Commissioner for Policy, Planning, Legislation, and Analysis. [FR Doc. 2017–20108 Filed 9–20–17; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration Notice of Single-Award Deviation From Competition Requirements for the Severe Combined Immunodeficiency (SCID) Newborn Screening Program at the Jeffrey Modell Foundation Health Resources and Services Administration (HRSA), Department of Health and Human Services. AGENCY: ACTION: HRSA announces the award of an extension in the amount of $2,000,000 for the Severe Combined Immunodeficiency (SCID) Newborn Screening program at the Jeffrey Modell Foundation (JMF). The extension will allow JMF, the cooperative agreement recipient, during the budget period of May 1, 2017 to April 30, 2018, to provide technical assistance and support to states for the implementation of population based newborn screening for SCID. FOR FURTHER INFORMATION CONTACT: Jill F. Shuger, ScM, Division of Services for Children with Special Health Needs, MCHB, HRSA, 5600 Fishers Lane, Rockville, Maryland 20857, Phone: (301) 443–3247, Email: JShuger@ hrsa.gov. SUPPLEMENTARY INFORMATION: Intended Recipient of the Award: Jeffrey Modell Foundation. Amount of Non-Competitive Awards: $2,000,000. Budget Period of Supplemental Funding: May 1, 2017 to April 30, 2018. CFDA Number: 93.110. Authority: Public Health Service Act, § 1109, as amended by the Newborn Screening Saves Lives Reauthorization Act of 2014 (Public Law 110–204) (42 U.S.C. 300b–8). SUMMARY: Notice of award. Justification: The Maternal and Child Health Bureau (MCHB) is proposing that JMF continue activities under the current cooperative agreement to ensure the implementation of newborn screening for SCID in all 50 states, particularly in the states that have yet to implement SCID screening (i.e., Alabama, Arizona, Indiana, Kansas, Louisiana, Nevada and North Carolina). Using its resources and centers, JMF will provide technical assistance in areas of funding, state government education, and linkage to expert care and patient access to a national network of specialized treatment centers. Further, JMF will continue to support states with implementation of SCID screening and follow up as well as the immediate treatment of infants identified with SCID. JMF will use the data collected from the states to educate clinical immunologists, neonatologists and other providers on effective screening for SCID. Additionally, JMF will continue to support education and awareness of newborn screening for SCID to families and health care providers and provide education to primary care providers and medically underserved populations. Grantee/organization name Grant No. State Fiscal year 2017 authorized funding level Jeffrey Modell Foundation ............................................................................... UG5MC28325 UT $2,000,000 Dated: September 7, 2017. George Sigounas, Administrator. property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. [FR Doc. 2017–20116 Filed 9–20–17; 8:45 am] BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health asabaliauskas on DSKBBXCHB2PROD with NOTICES National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial VerDate Sep<11>2014 19:03 Sep 20, 2017 Jkt 241001 Name of Committee: National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel; T32 Institutional Training Grant Review. Date: October 6, 2017. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Dental and Craniofacial Research, Democracy One, 6701 Democracy Blvd., Suite 602, Bethesda, MD 20892. Contact Person: Kan Ma, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, NIH, 6701 Democracy Boulevard, Suite 814, Bethesda, MD 20892, 301–451–4838, mak2@ mail.nih.gov. Name of Committee: National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel; Division of PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 44191 Fiscal year 2017 estimated supplemental funding $2,000,000 Musculoskeletal Diseases RISK R61/R33 Peer Review. Date: October 11, 2017. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Rd, Bethesda, MD 20852. Contact Person: Xincheng Zheng, MD, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, NIH, 6701 Democracy Boulevard, Suite 820, Bethesda, MD 20892, 301–451–4838, xincheng.zheng@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS) Dated: September 15, 2017. Sylvia L. Neal, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017–20095 Filed 9–20–17; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\21SEN1.SGM 21SEN1

Agencies

[Federal Register Volume 82, Number 182 (Thursday, September 21, 2017)]
[Notices]
[Page 44191]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-20116]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Notice of Single-Award Deviation From Competition Requirements
for the Severe Combined Immunodeficiency (SCID) Newborn Screening
Program at the Jeffrey Modell Foundation

AGENCY: Health Resources and Services Administration (HRSA), Department
of Health and Human Services.

ACTION: Notice of award.

-----------------------------------------------------------------------

SUMMARY: HRSA announces the award of an extension in the amount of
$2,000,000 for the Severe Combined Immunodeficiency (SCID) Newborn
Screening program at the Jeffrey Modell Foundation (JMF). The extension
will allow JMF, the cooperative agreement recipient, during the budget
period of May 1, 2017 to April 30, 2018, to provide technical
assistance and support to states for the implementation of population
based newborn screening for SCID.

FOR FURTHER INFORMATION CONTACT: Jill F. Shuger, ScM, Division of
Services for Children with Special Health Needs, MCHB, HRSA, 5600
Fishers Lane, Rockville, Maryland 20857, Phone: (301) 443-3247, Email:
JShuger@hrsa.gov.

SUPPLEMENTARY INFORMATION:
Intended Recipient of the Award: Jeffrey Modell Foundation.
Amount of Non-Competitive Awards: $2,000,000.
Budget Period of Supplemental Funding: May 1, 2017 to April 30,
2018.
CFDA Number: 93.110.
Authority: Public Health Service Act, Sec. 1109, as amended by the
Newborn Screening Saves Lives Reauthorization Act of 2014 (Public Law
110-204) (42 U.S.C. 300b-8).
Justification: The Maternal and Child Health Bureau (MCHB) is
proposing that JMF continue activities under the current cooperative
agreement to ensure the implementation of newborn screening for SCID in
all 50 states, particularly in the states that have yet to implement
SCID screening (i.e., Alabama, Arizona, Indiana, Kansas, Louisiana,
Nevada and North Carolina). Using its resources and centers, JMF will
provide technical assistance in areas of funding, state government
education, and linkage to expert care and patient access to a national
network of specialized treatment centers. Further, JMF will continue to
support states with implementation of SCID screening and follow up as
well as the immediate treatment of infants identified with SCID. JMF
will use the data collected from the states to educate clinical
immunologists, neonatologists and other providers on effective
screening for SCID. Additionally, JMF will continue to support
education and awareness of newborn screening for SCID to families and
health care providers and provide education to primary care providers
and medically underserved populations.

----------------------------------------------------------------------------------------------------------------
Fiscal year Fiscal year
2017 2017 estimated
Grantee/organization name Grant No. State authorized supplemental
funding level funding
----------------------------------------------------------------------------------------------------------------
Jeffrey Modell Foundation................... UG5MC28325 UT $2,000,000 $2,000,000
----------------------------------------------------------------------------------------------------------------

Dated: September 7, 2017.
George Sigounas,
Administrator.
[FR Doc. 2017-20116 Filed 9-20-17; 8:45 am]
BILLING CODE 4165-15-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.